Nadia Harbeck

机构：Deutsches Archäologisches Institut, Zentrale, LMU Klinikum, Klinik für Frauenheilkunde, München Klinik, Breast Center, Ludwig-Maximilians-Universität München · ORCID：0000-0002-9744-7372

发表论文 2105 篇 · 总被引 89508 次 · h-index 134

代表论文

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial (2026 · Annals of Oncology · 被引 17)
Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology (2026 · npj Breast Cancer · 被引 8)
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors (2025 · Radiotherapy and Oncology · 被引 7)
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy (2025 · Clinical Cancer Research · 被引 5)
Prediction of dose reductions and impact of reduced starting doses of CDK4 /6i on effectiveness in HR ‐positive/ HER2 ‐negative metastatic breast cancer: Real‐world data from the OPAL registry (2026 · International Journal of Cancer · 被引 3)
New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice (2026 · The Breast · 被引 2)